When assessed in a more recent study, this three-marker biosignature diagnosed TBM with improved sensitivity of 95.7% at the cost of specificity (37.5%), with better results obtained (sensitivity of 91.3% and specificity of 100%) when IL-13 and LL-37 were replaced by IFN-γ and myeloperoxidase (MPO), which was also for the diagnosis of TBM in children (88). The gene discussed is CAMP; the disease is meningeal tuberculosis.